Cancer Home > Alemtuzimab

Were you looking for information on Alemtuzumab? Alemtuzimab is a common misspelling of alemtuzumab.
Alemtuzumab (Campath®) is a drug used to treat a specific kind of chronic lymphocytic leukemia. It is available as an injection and is administered by a healthcare provider. In a clinical study, alemtuzumab was shown to extend the period of time leukemia does not progress, more so than chlorambucil (Leukeran®), another leukemia medicine. In the study, people who received alemtuzumab went about 14.6 months without their condition getting worse, compared with 11.7 months in people taking chlorambucil.
(Click Alemtuzumab to learn more about this medicine, including how it works, possible side effects, dosing guidelines, and more. You can also click any of the links in the box to the right for specific information.)
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation




Related Channels

eMedTV Links
Copyright © 2006-2019 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.